194
Participants
Start Date
September 30, 2022
Primary Completion Date
November 15, 2025
Study Completion Date
February 15, 2029
Obexelimab
Obexelimab is a monoclonal antibody that co-engages CD19 and FcγRIIb to inhibit B cell activity
Placebo
Placebo
Ajou University Hospital, Suwon
Linkou Chang Gung Memorial Hospital, Taoyuan District
Ospedale San Giovanni Bosco, Turin
Hôpitaux Universitaires de Marseille Timone, Saint-Pierre
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia
Hospital Universitario Ramón y Cajal, Madrid
Emory Univeristy, Atlanta
Haut-Lévèque Hospital Usn Building South Hospital Group, Pessac
GI PROS Research - Dedicated Research Facility, Naples
University of Verona, Verona
Henry Ford Hospital, Detroit
Stanford Medicine, Stanford
Massachusetts General Hospital, Boston
Hospital Italiano de Buenos Aires, Buenos Aires
Artus Health Centre, Vancouver
Center for Clinical Research (Nova Scotia Health), Halifax
Centre Hospitalier Universitaire de Sherbrooke CHUS, Sherbrooke
Chinese PLA General Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Peking University First Hospital, Beijing
The Second Hospital of Hebei Medical University, Shijiazhuang
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhai
Yantai Yuhuangding Hospital, Yantai
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Shanxi Bethune Hospital, Taiyuan
West China Hospital of Sichuan University, Chengdu
Hôpital Beaujon, Paris
Hôpital de la Pitié Salpétrière, Paris
LMU Klinikum der Universität München, München
Universitätsklinikum Ulm, Ulm
Azienda Ospedaliera Universitaria Meyer Istituto di Ricovero e Cura a Carattere Scientifico, Florence
Ospedale San Raffaele S.r.l. - PPDS, Milan
Kanazawa Medical University Hospital, Kokura
Kanazawa University Hospital, Kanazawa
Kagawa University Hospital, Hiragi
Osaka Metropolitan University Hospital, Osaka
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyō-Ku
The Institute of Medical Science, The University of Tokyo Hospital, Minato-ku
Keio University Hospital, Shinjuku-Ku
Toyama University Hospital, Toyama
Kansai Medical University Hospital, Hirakata
Hiroshima University Hospital, Hiroshima
St. Marianna University Hospital, Kawasaki
Tokyo Medical Center Hospital, Meguro City
Nagaoka Red Cross Hospital, Nagaoka
Nagasaki University Hospital, Nagasaki
Kita-Harima Medical Center, Ono
Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka
Sapporo Medical University Hospital, Sapporo
Fujita Health University Hospital, Shinjuku-Ku
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City
Centro de Alta Especialidad En Reumatologia E Investigacion Del Potosi SC, San Luis Potosí City
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. Prof. Dr hab. Med. Eleonory Reicher, Warsaw
Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz
Hospital Universitario Virgen del Rocio, Seville
Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Taipei Veterans General Hospital, Taipei
Marmara University Pendik Training and Research Hospital, Pendik
John Radcliffe Hospital, Oxford
Hospital of University of Occupational and Environmental Health, Kitakyushu
Shinshu University Hospital, Matsumoto
Seoul National University Hospital, Seoul
Hospital de la Santa Creu i Sant Pau, Barcelona
Vall d'Hebron University Hospital, Barcelona
Hacettepe University Faculty of Medicine, Altındağ
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Zenas BioPharma (USA), LLC
INDUSTRY